Trial Profile
Apatinib Plus Docetaxel or pemetrexed Versus Docetaxel or pemetrexed as Second-line Treatment in advanced non-small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Jan 2018 New trial record